Ken Griffin Lipocine Inc. Transaction History

Citadel Advisors LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.3 - $0.58 $3,959 - $7,655	-13,199 Reduced 12.38%	93,393 $29,000
Q4 2022 Feb 14, 2023	SELL	$0.37 - $8.65 $69,864 - $1.63 Million	-188,824 Reduced 63.92%	106,592 $42,000
Q3 2022 Nov 14, 2022	BUY	$0.49 - $7.65 $144,753 - $2.26 Million	295,416 New	295,416 $133,000
Q1 2022 May 16, 2022	BUY	$0.89 - $1.85 $24,501 - $50,930	27,530 Added 77.32%	63,135 $86,000
Q4 2021 Feb 14, 2022	SELL	$0.99 - $1.2 $19,814 - $24,018	-20,015 Reduced 35.99%	35,605 $35,000
Q3 2021 Nov 15, 2021	BUY	$1.08 - $1.49 $14,955 - $20,633	13,848 Added 33.15%	55,620 $61,000
Q1 2021 May 17, 2021	SELL	$1.38 - $2.28 $45,701 - $75,506	-33,117 Reduced 44.22%	41,772 $63,000
Q4 2020 Feb 16, 2021	BUY	$1.2 - $1.69 $75,313 - $106,066	62,761 Added 517.49%	74,889 $102,000
Q3 2020 Nov 16, 2020	SELL	$1.21 - $2.23 $156 - $287	-129 Reduced 1.05%	12,128 $17,000
Q1 2020 May 15, 2020	BUY	$0.32 - $0.77 $3,922 - $9,437	12,257 New	12,257 $6,000
Q2 2019 Aug 14, 2019	SELL	$1.43 - $2.32 $14,800 - $24,012	-10,350 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$1.46 - $2.33 $3,912 - $6,244	-2,680 Reduced 20.57%	10,350 $0
Q4 2018 Feb 14, 2019	SELL	$1.07 - $1.63 $3,594 - $5,475	-3,359 Reduced 20.5%	13,030 $16,000
Q2 2018 Aug 10, 2018	BUY	$1.06 - $1.78 $17,372 - $29,172	16,389 New	16,389 $0

Ticker LPCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 88,510,800
Market Cap $431M
Description
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone rep...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.